Skip to content
Clinical Trials – home

Med Polonia Sp. z o.o.

Verifiedinfo

Poland Obornicka 262, 60-693 Poznan, Poland

  • 26 trials recruiting
  • Non-small cell lung cancer · Non-small cell lung cancer metastatic · Non-small cell lung cancer stage IV
  • Adults and children

About Specializations

Med Polonia Sp. z o.o. in Poznan, Poland specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer metastatic, Non-small cell lung cancer stage IV, Neoplasm malignant, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, focusing on innovative treatments for various types of lung cancer. The center's work in this field is characterized by its exploration of novel therapeutic combinations and targeted therapies.

  • Extensive-stage small-cell lung cancer
  • Non-small cell lung cancer (NSCLC)
  • Renal cell carcinoma

By integrating cutting-edge research with clinical practice, the center is advancing the understanding and treatment of complex cancer types, offering hope for improved patient outcomes.

Neurology

Specializing in neurology, the center is dedicated to advancing the treatment of neurological disorders, with a particular focus on multiple sclerosis. The research conducted here aims to enhance the safety and efficacy of emerging therapies.

  • Relapsing forms of multiple sclerosis
  • Relapsing-remitting multiple sclerosis

Through rigorous clinical trials, the center is contributing to the development of new therapeutic strategies that aim to improve the quality of life for patients with neurological conditions.

Immunology

The center's immunology research is focused on understanding and treating autoimmune diseases, with a particular emphasis on Sjögren's syndrome. This research is pivotal in developing therapies that target the underlying mechanisms of immune dysfunction.

  • Sjögren's syndrome

By exploring novel immunomodulatory treatments, the center is paving the way for more effective management of autoimmune diseases, enhancing patient care and outcomes.

Endocrinology

In the field of endocrinology, the center is pioneering research into the treatment of diabetic complications, particularly focusing on innovative approaches to healing diabetic foot ulcers.

  • Diabetic foot ulcers

The center's research efforts are directed towards developing topical treatments that promote wound healing, thereby reducing the risk of severe complications and improving patient quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Obornicka 26260-693 PoznanPoland
Recruiting now
26 trials
Conditions studied
43
Partner status
Verified

More sites in PoznanPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

93 clinical trials

Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:IMEROPRUBART
  • Sponsor:Immunovant Sciences GmbH
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
  • Sponsor:Genmab A/S
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.